Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.

The negative co-stimulatory receptor, programmed cell death 1 (PD-1), is induced on activated T cells and delivers inhibitory signals upon engagement with its ligands PD-L1 and PD-L2, which are expressed on various somatic cells and certain cancers. Accumulating evidence suggests that interfering with the PD-1-PD-L1 interaction may result in the restoration of defective T cell functions in cancer and chronic viral infection. Herein, we established procedures to produce large amounts of renatured recombinant extracellular domain proteins of mouse PD-1 (mPD-1) and PD-L1. While monomeric mPD-1 and mouse PD-L1 (mPD-L1) only marginally interacted with the cells expressing their counterpart proteins, their tetramerization markedly enhanced the affinity with the K(d) of mPD-L1 tetramer being nearly 100-fold lower than that of the corresponding monomer. The affinity of mPD-L1 tetramer was even higher than a high-affinity anti-PD-1 mAb, and it efficiently inhibited the binding of mPD-L1/Fc-chimeric protein to mPD-1(+) cells. Functionally, mPD-L1 tetramer significantly enhanced the proliferative responses as well as the cytotoxic activity of T cells against specific target cells in vitro. The results suggest that oligomeric PD-L1 extracellular domains may provide a potential means to restore T cell functions in cancer and viral infection in humans.

[1]  R. Koup,et al.  PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection , 2006, The Journal of experimental medicine.

[2]  Philip J. R. Goulder,et al.  PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression , 2006, Nature.

[3]  R. Balderas,et al.  Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.

[4]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[5]  T. Okazaki,et al.  Hydronephrosis associated with antiurothelial and antinuclear autoantibodies in BALB/c-Fcgr2b −/− Pdcd1 −/− mice , 2005, The Journal of experimental medicine.

[6]  P. Saunders,et al.  PD‐L2:PD‐1 involvement in T cell proliferation, cytokine production, and integrin‐mediated adhesion , 2005, European journal of immunology.

[7]  T. Okazaki,et al.  Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[8]  M. Azuma,et al.  Clinical Significance of Programmed Death-1 Ligand-1 and Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer , 2005, Clinical Cancer Research.

[9]  D. Stuart,et al.  Crystal structure of a soluble CD28-Fab complex , 2005, Nature Immunology.

[10]  G. Zhu,et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. , 2005, Cancer research.

[11]  T. Honjo,et al.  PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. , 2004, International immunology.

[12]  M. Nishimura,et al.  B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression , 2004, Clinical Cancer Research.

[13]  C. June,et al.  SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1 , 2004, The Journal of Immunology.

[14]  S. Almo,et al.  Erratum: Structural and functional analysis of the costimulatory receptor programmed death-1 (Immunity (March 2004) 20 (337-347)) , 2004 .

[15]  Michael Cammer,et al.  Structural and functional analysis of the costimulatory receptor programmed death-1. , 2004, Immunity.

[16]  Yoshimasa Tanaka,et al.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice , 2003, Nature Medicine.

[17]  G. Freeman,et al.  Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses , 2003, European journal of immunology.

[18]  J. Cheville,et al.  B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. , 2003, Cancer research.

[19]  S. Khoury,et al.  Critical Role of the Programmed Death-1 (PD-1) Pathway in Regulation of Experimental Autoimmune Encephalomyelitis , 2003, The Journal of experimental medicine.

[20]  S. Khoury,et al.  The Programmed Death-1 (PD-1) Pathway Regulates Autoimmune Diabetes in Nonobese Diabetic (NOD) Mice , 2003, The Journal of experimental medicine.

[21]  T. Okazaki,et al.  PD-1 Inhibits Antiviral Immunity at the Effector Phase in the Liver , 2003, The Journal of experimental medicine.

[22]  T. Curiel,et al.  Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity , 2003, Nature Medicine.

[23]  G. Freeman,et al.  Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. , 2002, Immunology letters.

[24]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.

[26]  H. Schneider,et al.  A regulatory role for cytoplasmic YVKM motif in CTLA‐4 inhibition of TCR signaling , 2001, European journal of immunology.

[27]  T. Honjo,et al.  PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. , 2001, Trends in immunology.

[28]  D. Pardoll,et al.  B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells , 2001, The Journal of experimental medicine.

[29]  C. Chambers The expanding world of co-stimulation: the two-signal model revisited. , 2001, Trends in immunology.

[30]  G. Freeman,et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation , 2001, Nature Immunology.

[31]  T. Okazaki,et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. , 2001, Science.

[32]  G. Freeman,et al.  Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation , 2000, The Journal of experimental medicine.

[33]  S. Dzik B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin 10 secretion , 2000 .

[34]  T. Honjo,et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. , 1999, Immunity.

[35]  P. Schwartzberg,et al.  Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4. , 1998, Biochemical and biophysical research communications.

[36]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[37]  D. Olive,et al.  Binding of phosphatidyl-inositol-3-OH kinase to CD28 is required for T-cell signalling , 1994, Nature.

[38]  A. Weiss,et al.  The cytoplasmic domain of CD28 is both necessary and sufficient for costimulation of interleukin-2 secretion and association with phosphatidylinositol 3'-kinase , 1994, Molecular and cellular biology.

[39]  L. Cantley,et al.  T-cell antigen CD28 interacts with the lipid kinase phosphatidylinositol 3-kinase by a cytoplasmic Tyr(P)-Met-Xaa-Met motif. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[40]  P. Schatz Use of Peptide Libraries to Map the Substrate Specificity of a Peptide-Modifying Enzyme: A 13 Residue Consensus Peptide Specifies Biotinylation in Escherichia coli , 1993, Bio/Technology.

[41]  C. Nelson,et al.  Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice , 1988, Nature.

[42]  R. Lloubès,et al.  Translation is a non-uniform process. Effect of tRNA availability on the rate of elongation of nascent polypeptide chains. , 1984, Journal of molecular biology.

[43]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[44]  岡崎 拓 PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine , 2003 .

[45]  S. Almo,et al.  Structural mechanisms of costimulation , 2002, Nature Immunology.

[46]  D. Olive,et al.  Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling , 1994, Nature.

[47]  G D Stormo,et al.  High-level translation initiation. , 1990, Methods in enzymology.